Anebulo Pharmaceuticals (ANEB) Net Cash Flow (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Net Cash Flow of -$1.3 million for Q4 2025, up 6.58% year-over-year from -$1.2 million in Q4 2024, and down 3.15% quarter-over-quarter from -$1.3 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Net Cash Flow (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Net Cash Flow for 6 consecutive years, with -$1.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Cash Flow rose 6.58% year-over-year to -$1.3 million; the TTM figure through Dec 2025 stood at -$6.0 million (up 10.37% YoY), while the FY2025 annual figure was $8.5 million, up 204.67% from the prior year.
- Net Cash Flow fell to -$1.3 million in Q4 2025 per ANEB's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $16.7 million in Q2 2021 and bottomed at -$2.9 million in Q2 2023.
- Historically, Net Cash Flow has averaged -$501603.2 across 5 years, with a median of -$1.6 million in 2024.
- Annual changes were most pronounced in 2021 — Net Cash Flow plunged 476.41% — and 2022, when it surged 699.72%.
- Anebulo Pharmaceuticals' Net Cash Flow stood at -$1.2 million in 2021, then slumped by 138.44% to -$2.9 million in 2022, then soared by 36.55% to -$1.8 million in 2023, then grew by 22.49% to -$1.4 million in 2024, then gained by 6.58% to -$1.3 million in 2025.
- Business Quant data shows ANEB's Net Cash Flow at -$1.3 million in Q4 2025, -$1.3 million in Q3 2025, and -$1.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | -1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.31 Mn |
| Dec 31, 2025 | -1.31 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | -1.65 Mn |
| Jun 30, 2025 | -1.65 Mn |
| Mar 31, 2025 | -1.72 Mn |
| Mar 31, 2025 | -1.72 Mn |
| Dec 31, 2024 | -1.41 Mn |
| Dec 31, 2024 | -1.41 Mn |
| Sep 30, 2024 | -1.69 Mn |
| Sep 30, 2024 | -1.69 Mn |
| Jun 30, 2024 | -2.05 Mn |
| Jun 30, 2024 | -2.05 Mn |
| Mar 31, 2024 | -1.50 Mn |
| Mar 31, 2024 | -1.50 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Sep 30, 2023 | -2.73 Mn |
| Sep 30, 2023 | -2.73 Mn |